Nature Communications (Jan 2021)
Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma
- Giulia Agliardi,
- Anna Rita Liuzzi,
- Alastair Hotblack,
- Donatella De Feo,
- Nicolás Núñez,
- Cassandra L. Stowe,
- Ekaterina Friebel,
- Francesco Nannini,
- Lukas Rindlisbacher,
- Thomas A. Roberts,
- Rajiv Ramasawmy,
- Iwan P. Williams,
- Bernard M. Siow,
- Mark F. Lythgoe,
- Tammy L. Kalber,
- Sergio A. Quezada,
- Martin A. Pule,
- Sonia Tugues,
- Karin Straathof,
- Burkhard Becher
Affiliations
- Giulia Agliardi
- Research Department of Hematology, Cancer Institute, University College London
- Anna Rita Liuzzi
- Institute of Experimental Immunology, University of Zurich
- Alastair Hotblack
- Research Department of Hematology, Cancer Institute, University College London
- Donatella De Feo
- Institute of Experimental Immunology, University of Zurich
- Nicolás Núñez
- Institute of Experimental Immunology, University of Zurich
- Cassandra L. Stowe
- Research Department of Hematology, Cancer Institute, University College London
- Ekaterina Friebel
- Institute of Experimental Immunology, University of Zurich
- Francesco Nannini
- Research Department of Hematology, Cancer Institute, University College London
- Lukas Rindlisbacher
- Institute of Experimental Immunology, University of Zurich
- Thomas A. Roberts
- Centre for Advanced Biomedical Imaging (CABI), University College London
- Rajiv Ramasawmy
- Centre for Advanced Biomedical Imaging (CABI), University College London
- Iwan P. Williams
- Research Department of Hematology, Cancer Institute, University College London
- Bernard M. Siow
- Centre for Advanced Biomedical Imaging (CABI), University College London
- Mark F. Lythgoe
- Centre for Advanced Biomedical Imaging (CABI), University College London
- Tammy L. Kalber
- Centre for Advanced Biomedical Imaging (CABI), University College London
- Sergio A. Quezada
- Research Department of Hematology, Cancer Institute, University College London
- Martin A. Pule
- Research Department of Hematology, Cancer Institute, University College London
- Sonia Tugues
- Institute of Experimental Immunology, University of Zurich
- Karin Straathof
- Research Department of Hematology, Cancer Institute, University College London
- Burkhard Becher
- Institute of Experimental Immunology, University of Zurich
- DOI
- https://doi.org/10.1038/s41467-020-20599-x
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 11
Abstract
Glioblastoma multiform (GBM) is a common and aggressive type of primary brain cancer that currently has no effective therapy. Here, the authors show, using a mouse GBM model and EGFRvIII-targeting chimeric antigen receptor (CAR)-T cells, that Intratumoral injection of interleukin-12 helps condition the microenvironment and promote anti-tumor immunity.
